Navigation Links
Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
Date:7/22/2008

FDA Meeting to Discuss Development Plan Completed Successfully

DUBLIN, Ireland, July 22 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company recently met with officials at the U.S. Food and Drug Administration (FDA) to discuss the Company's plans to develop AMR101 for the treatment of hypertriglyceridemia. Following these discussions, the Company is proceeding to Phase 3 with AMR101 in hypertriglyceridemia.

Dr. Declan Doogan, Head of Research and Development of Amarin, commented: "The meeting with the FDA was very successful as it gives us a clear path forward for the program. We are particularly pleased that we can proceed to Phase 3."

Thomas Lynch, Chairman and Chief Executive Officer of Amarin, added: "Over the past year we have assembled a highly experienced team of cardiovascular experts to develop AMR101 for this significant indication. Our initial objective of designing the Phase 3 program and obtaining FDA feedback has been achieved. Having completed our recent financing, we now look forward to conducting the Phase 3 program."

AMR101 is an ultra-pure ethyl ester of eicosapentaenoic acid (Ethyl-EPA). Amarin has collected a substantial body of data on AMR101 to date. Amarin has previously investigated AMR101 in central nervous system (CNS) disorders in several double-blind, placebo controlled studies, including Phase 3 trials in Huntington's disease. Over 900 patients have received AMR101 in these studies, with over 100 receiving continuous treatment for a year or more. In all studies performed to date, AMR101 has shown a very good safety profile.

Hypertriglyceridemia refers to a condition in which patients have high blood levels of triglycerides and i
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
2. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
3. Mayo Clinic Proceedings Contributors Highlight Research Findings About Cardiovascular Benefits Associated With Omega-3 Fatty Acids
4. Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System
5. Mayo Clinic Proceedings January Tip Sheet
6. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
7. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
8. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
9. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
10. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
11. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Nov. 28, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... company with a focus on Omega-3 therapies for ... accomplishments and financial results for the three months ... herein are in Canadian dollars unless otherwise stated. ... expanded its product line to address new market ...
(Date:11/28/2014)... , Nov. 28, 2014 The market ... to reach 7.9 billion dollars in 2014 according to ... of existing equipment and growing incidence of disease are ... Information,s X-Ray and Digital X-Ray: World Market Analysis ... Digital X-Ray: World Market Analysis can be obtained ...
(Date:11/28/2014)... 2014  (Booth #7309, North Hall) — Dicom ... product, DCMSYS Interface WebBridge, at the 100th annual RSNA ... Place, Chicago, Illinois . ... Designed for medical facilities of any size, WebBridge allows ... any non-standard data (e.g. JPEG, TFF, PDF, TXT, etc.) ...
Breaking Medicine Technology:Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results 2Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results 3Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results 4Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results 5Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results 6Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 2Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 3Dicom Systems Announces WebBridge Interface at RSNA 2014 2
... 21 Whenever there is a security ... (PHI), the healthcare industry is now required under ... assessment.  ID Experts®, the leader in comprehensive data ... today announced RADAR—Risk Assessment Documentation and Reporting—the industry,s ...
... 21 Alere Inc. (formerly known as Inverness Medical Innovations, ... individuals to take charge of their health at home through the ... will release its second quarter 2010 earnings on Wednesday, July ... beginning at 10:00 a.m. (Eastern Time) on that date ...
Cached Medicine Technology:ID Experts Announces RADAR™: A HITECH Risk Assessment Tool for Healthcare Security Breach Incidents Affecting Patient Privacy 2ID Experts Announces RADAR™: A HITECH Risk Assessment Tool for Healthcare Security Breach Incidents Affecting Patient Privacy 3Alere Inc. Schedules Conference Call for 10:00 a.m. ET July 28, 2010 to Discuss Second Quarter 2010 Results 2
(Date:11/28/2014)... Junk-A-Car ( http://www.junkacar.com ), one of the ... to help drivers, especially those in and around the ... areas deal with the especially harsh winter weather that ... the country. , With the high number of reported ... crashed and junk cars, Junk-A-Car is voluntarily ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Novatus, ... announced its Release v5.1 which provides customers with ... workflow options. , “As we continue to ... to provide more functionality and improved performance in ... Gambotz, CEO for Novatus. “With the enhancements that ...
(Date:11/28/2014)... November 28, 2014 Mirena lawsuits ... forward in New Jersey’s Bergen County Superior Court, ... litigation established there is quickly approaching 1,300, Bernstein ... November 18th shows 1,293 lawsuits now pending in ... that allege complications resulting from spontaneous migration of ...
(Date:11/28/2014)... Walder, one of South Florida’s top cosmetic dermatologists , ... that is designed to help her patients reduce unwanted fat ... has been praised by patients as being permanent, painless, and ... types of external fat reduction. , “If you can pinch ... According to Dr. Walder, Ultrashape works by targeting subcutaneous fat, ...
(Date:11/28/2014)... Dr. Paul Vitenas, one of the most awarded cosmetic ... Event for those in the area that would like to learn ... Glow will take place on December 11, 2014, from 6:00 p.m. ... of Houston at 4208 Richmond Ave. , “We want to ... come and celebrate the season with us on December 11, 2014 ...
Breaking Medicine News(10 mins):Health News:Junk-A-Car Expanding Service to Assist U.S. Car Owners That May be Affected by Severe Winter Storms 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3
... Prenatal Solution Key Factor in Decision for ... Jan. 8 Allscripts announced today that ... multi-specialty group practices in the Southeast United ... Health Record (EHR) to automate and connect ...
... Hospital have demonstrated a more effective treatment for ... antibiotics clindamycin and azithromycin, which kill bacteria by ... a standard first-line treatment with the "beta-lactam" antibiotic ... burst. , The finding is important ...
... 8 Allscripts-Misys Healthcare,Solutions, Inc., formerly Allscripts Healthcare ... financial results for the three and six,months ended ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061005/ALLSCRIPTSLOGO-b ) , ... six months ended November 30, 2008,include results from ...
... 8 /PRNewswire-Asia/ -- Chindex International, Inc.,(Nasdaq: CHDX ... of Western healthcare products and services in the People,s ... the 2009 UBS Greater,China Conference, to be held in ... The 2009 UBS Greater China Conference will ...
... should be used when assessing traditional risk factors, experts say ... -- or "biomarkers" -- of inflammation may provide useful information ... research says. , "If you are very high or very ... said study lead author Dr. Vijay Nambi, a cardiologist at ...
... business continues to drive overall performanceDALLAS, Jan. 8 ... leader in hosted services for email encryption and e-prescribing, ... officer, Rick Spurr."We ended the year on a high ... the highest orders for the year in the fourth ...
Cached Medicine News:Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 2Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 3Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 4
... Multimode Detectors provide unmatched value and ... and automation needs. Capable of performing ... the same instrument, the DTX Series ... can be integrated seamlessly with Beckman ...
... Screening (HTS), Analyst HT smoothes the ... sharing all the detection modalities and ... intensity, fluorescence polarization, time-resolved fluorescence, luminescence, ... into robotic environments, including those from ...
... the right features for assay development ... instrument control. Reduces the inevitable transfer ... HTS. Specifically developed to meet the ... AD delivers unparalleled detection performance for ...
... a flexible multifunction plate reader that offers ... fluorescence intensity, time-resolved fluorescence, high-perfomance luminescence and ... with injectors that deliver reagent at the ... cell assays can be performed easily and ...
Medicine Products: